Mercer Global Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $36.7M | Buy |
636,124
+47,633
| +8% | +$2.74M | 0.05% | 228 |
|
|
2026
Q1 | $35.7M | Buy |
588,491
+127,574
| +28% | +$7.44M | 0.05% | 222 |
|
|
2025
Q4 | $23.9M | Buy |
460,917
+172,632
| +60% | +$8.3M | 0.04% | 294 |
|
|
2025
Q3 | $13M | Buy |
288,285
+41,405
| +17% | +$1.93M | 0.02% | 404 |
|
|
2025
Q2 | $11.4M | Sell |
246,880
-18,494
| -7% | -$908K | 0.02% | 358 |
|
|
2025
Q1 | $16.2M | Buy |
265,374
+1,095
| +0.4% | +$63.8K | 0.04% | 266 |
|
|
2024
Q4 | $14.9M | Sell |
264,279
-109,473
| -29% | -$6.12M | 0.04% | 271 |
|
|
2024
Q3 | $19.7M | Sell |
373,752
-8,396
| -2% | -$394K | 0.05% | 210 |
|
|
2024
Q2 | $12.5M | Sell |
382,148
-228,726
| -37% | -$10.2M | 0.03% | 265 |
|
|
2024
Q1 | $33.1M | Buy |
610,874
+143,127
| +31% | +$7.29M | 0.09% | 144 |
|
|
2023
Q4 | $24M | Buy |
467,747
+1,082
| +0.2% | +$56.8K | 0.07% | 171 |
|
|
2023
Q3 | $27.1M | Sell |
466,665
-17,802
| -4% | -$1.09M | 0.1% | 125 |
|
|
2023
Q2 | $31M | Sell |
484,467
-695
| -0.1% | -$46.6K | 0.12% | 116 |
|
|
2023
Q1 | $33.6M | Buy |
485,162
+74,427
| +18% | +$5.25M | 0.15% | 101 |
|
|
2022
Q4 | $29.6M | Buy |
410,735
+104,541
| +34% | +$7.88M | 0.15% | 107 |
|
|
2022
Q3 | $21.8M | Buy |
306,194
+33,099
| +12% | +$2.4M | 0.13% | 127 |
|
|
2022
Q2 | $21M | Buy |
273,095
+31,380
| +13% | +$2.39M | 0.13% | 124 |
|
|
2022
Q1 | $17.7M | Buy |
241,715
+118,989
| +97% | +$7.99M | 0.1% | 151 |
|
|
2021
Q4 | $7.65M | Sell |
122,726
-788
| -0.6% | -$46.2K | 0.05% | 286 |
|
|
2021
Q3 | $7.31M | Buy |
123,514
+9,272
| +8% | +$611K | 0.05% | 276 |
|
|
2021
Q2 | $7.63M | Buy |
114,242
+9,420
| +9% | +$614K | 0.06% | 254 |
|
|
2021
Q1 | $6.62M | Sell |
104,822
-30,835
| -23% | -$1.92M | 0.06% | 255 |
|
|
2020
Q4 | $8.41M | Buy |
135,657
+5,057
| +4% | +$311K | 0.11% | 147 |
|
|
2020
Q3 | $7.87M | Buy |
130,600
+21,365
| +20% | +$1.29M | 0.12% | 130 |
|
|
2020
Q2 | $6.42M | Buy |
109,235
+21,099
| +24% | +$1.26M | 0.12% | 129 |
|
|
2020
Q1 | $4.91M | Buy |
88,136
+39,149
| +80% | +$2.39M | 0.11% | 160 |
|
|
2019
Q4 | $3.14M | Buy |
48,987
+6,015
| +14% | +$344K | 0.06% | 248 |
|
|
2019
Q3 | $2.18M | Buy |
42,972
+2,225
| +5% | +$105K | 0.05% | 289 |
|
|
2019
Q2 | $1.85M | Buy |
40,747
+4,554
| +13% | +$212K | 0.05% | 303 |
|
|
2019
Q1 | $1.73M | Buy |
+36,193
| New | +$1.8M | 0.06% | 272 |
|
Other funds holding BMY
Mercer Global Advisors's BMY Position: Q2 2026 in Review
Mercer Global Advisors increased its Bristol-Myers Squibb (BMY) stake by 8.1% in Q2 2026, buying an estimated $2.74M and bringing the position to 636,124 shares worth $36.7M. The position accounts for 0.05% of the portfolio, ranked #228.
Mercer Global Advisors first reported a position in BMY in Q1 2019 and has held it in 30 quarters since. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Mercer Global Advisors held 636,124 shares of Bristol-Myers Squibb worth $36.7M as of Q2 2026.
- Mercer Global Advisors bought 47,633 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.74M.
- Bristol-Myers Squibb made up 0.05% of Mercer Global Advisors's portfolio in Q2 2026, its #228 holding.
- Mercer Global Advisors first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 30 quarters since.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.